Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis.

Recent clinical trials have established B cell depletion by the anti-CD20 chimeric antibody Rituximab as a beneficial therapy for patients with relapsing-remitting multiple sclerosis (MS). The impact of Rituximab on T cell responses remains largely unexplored. In the experimental autoimmune encephal...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nancy L Monson, Petra Cravens, Rehana Hussain, Christopher T Harp, Matthew Cummings, Maria de Pilar Martin, Li-Hong Ben, Julie Do, Jeri-Anne Lyons, Amy Lovette-Racke, Anne H Cross, Michael K Racke, Olaf Stüve, Mark Shlomchik, Todd N Eagar
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2011
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/7eb457a109ad42ca8f3e5a28c0d1260d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7eb457a109ad42ca8f3e5a28c0d1260d
record_format	dspace
spelling	oai:doaj.org-article:7eb457a109ad42ca8f3e5a28c0d1260d2021-11-18T06:58:41ZRituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis.1932-620310.1371/journal.pone.0017103https://doaj.org/article/7eb457a109ad42ca8f3e5a28c0d1260d2011-02-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21359213/?tool=EBIhttps://doaj.org/toc/1932-6203Recent clinical trials have established B cell depletion by the anti-CD20 chimeric antibody Rituximab as a beneficial therapy for patients with relapsing-remitting multiple sclerosis (MS). The impact of Rituximab on T cell responses remains largely unexplored. In the experimental autoimmune encephalomyelitis (EAE) model of MS in mice that express human CD20, Rituximab administration rapidly depleted peripheral B cells and strongly reduced EAE severity. B cell depletion was also associated with diminished Delayed Type Hypersensitivity (DTH) and a reduction in T cell proliferation and IL-17 production during recall immune response experiments. While Rituximab is not considered a broad immunosuppressant, our results indicate a role for B cells as a therapeutic cellular target in regulating encephalitogenic T cell responses in specific tissues.Nancy L MonsonPetra CravensRehana HussainChristopher T HarpMatthew CummingsMaria de Pilar MartinLi-Hong BenJulie DoJeri-Anne LyonsAmy Lovette-RackeAnne H CrossMichael K RackeOlaf StüveMark ShlomchikTodd N EagarPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 6, Iss 2, p e17103 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Nancy L Monson Petra Cravens Rehana Hussain Christopher T Harp Matthew Cummings Maria de Pilar Martin Li-Hong Ben Julie Do Jeri-Anne Lyons Amy Lovette-Racke Anne H Cross Michael K Racke Olaf Stüve Mark Shlomchik Todd N Eagar Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis.
description	Recent clinical trials have established B cell depletion by the anti-CD20 chimeric antibody Rituximab as a beneficial therapy for patients with relapsing-remitting multiple sclerosis (MS). The impact of Rituximab on T cell responses remains largely unexplored. In the experimental autoimmune encephalomyelitis (EAE) model of MS in mice that express human CD20, Rituximab administration rapidly depleted peripheral B cells and strongly reduced EAE severity. B cell depletion was also associated with diminished Delayed Type Hypersensitivity (DTH) and a reduction in T cell proliferation and IL-17 production during recall immune response experiments. While Rituximab is not considered a broad immunosuppressant, our results indicate a role for B cells as a therapeutic cellular target in regulating encephalitogenic T cell responses in specific tissues.
format	article
author	Nancy L Monson Petra Cravens Rehana Hussain Christopher T Harp Matthew Cummings Maria de Pilar Martin Li-Hong Ben Julie Do Jeri-Anne Lyons Amy Lovette-Racke Anne H Cross Michael K Racke Olaf Stüve Mark Shlomchik Todd N Eagar
author_facet	Nancy L Monson Petra Cravens Rehana Hussain Christopher T Harp Matthew Cummings Maria de Pilar Martin Li-Hong Ben Julie Do Jeri-Anne Lyons Amy Lovette-Racke Anne H Cross Michael K Racke Olaf Stüve Mark Shlomchik Todd N Eagar
author_sort	Nancy L Monson
title	Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis.
title_short	Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis.
title_full	Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis.
title_fullStr	Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis.
title_full_unstemmed	Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis.
title_sort	rituximab therapy reduces organ-specific t cell responses and ameliorates experimental autoimmune encephalomyelitis.
publisher	Public Library of Science (PLoS)
publishDate	2011
url	https://doaj.org/article/7eb457a109ad42ca8f3e5a28c0d1260d
work_keys_str_mv	AT nancylmonson rituximabtherapyreducesorganspecifictcellresponsesandamelioratesexperimentalautoimmuneencephalomyelitis AT petracravens rituximabtherapyreducesorganspecifictcellresponsesandamelioratesexperimentalautoimmuneencephalomyelitis AT rehanahussain rituximabtherapyreducesorganspecifictcellresponsesandamelioratesexperimentalautoimmuneencephalomyelitis AT christophertharp rituximabtherapyreducesorganspecifictcellresponsesandamelioratesexperimentalautoimmuneencephalomyelitis AT matthewcummings rituximabtherapyreducesorganspecifictcellresponsesandamelioratesexperimentalautoimmuneencephalomyelitis AT mariadepilarmartin rituximabtherapyreducesorganspecifictcellresponsesandamelioratesexperimentalautoimmuneencephalomyelitis AT lihongben rituximabtherapyreducesorganspecifictcellresponsesandamelioratesexperimentalautoimmuneencephalomyelitis AT juliedo rituximabtherapyreducesorganspecifictcellresponsesandamelioratesexperimentalautoimmuneencephalomyelitis AT jeriannelyons rituximabtherapyreducesorganspecifictcellresponsesandamelioratesexperimentalautoimmuneencephalomyelitis AT amylovetteracke rituximabtherapyreducesorganspecifictcellresponsesandamelioratesexperimentalautoimmuneencephalomyelitis AT annehcross rituximabtherapyreducesorganspecifictcellresponsesandamelioratesexperimentalautoimmuneencephalomyelitis AT michaelkracke rituximabtherapyreducesorganspecifictcellresponsesandamelioratesexperimentalautoimmuneencephalomyelitis AT olafstuve rituximabtherapyreducesorganspecifictcellresponsesandamelioratesexperimentalautoimmuneencephalomyelitis AT markshlomchik rituximabtherapyreducesorganspecifictcellresponsesandamelioratesexperimentalautoimmuneencephalomyelitis AT toddneagar rituximabtherapyreducesorganspecifictcellresponsesandamelioratesexperimentalautoimmuneencephalomyelitis
_version_	1718424114192973824

Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis.

Ejemplares similares